Stockreport

Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal [Yahoo! Finance]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF On March 30, Reuters reported that Royalty Pharma entered into a $500 million research and development agreement with Johnson & Johnson (NYSE:JNJ) to support an experim [Read more]